ArticleBlood advances2026
TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAndexanet alfa (AndA) is a modified, inactive form of coagulation factor Xa (FXa) and is the only selective reversal agent for direct oral anti-FXa inhibitors. Due to its similarity to FXa, AndA binds the endogenous anticoagulant, tissue factor pathway inhibitor α (TFPIα). We determined how AndA affects TFPIα function and enhancement by its cofactors, protein S and FV-short. AndA reversed rivaroxaban-mediated suppression of thrombin generation in plasma. In the absence of rivaroxaban, AndA (0.25μM-4μM) increased peak thrombin ∼22-fold, but had no impact on the presence of anti-TFPIα antibodies, suggesting AndA inhibited TFPIα anticoagulant function. However, AndA did not fully block TFPIα, with ∼20% to 30% function remaining at 2μM-4μM AndA. This preserved TFPIα function was fully inhibited by anti-protein S antibodies, suggesting partial protection of TFPIα function by its cofactors. In pure-component FXa inhibition assays, AndA fully blocked TFPIα-mediated FXa inhibition, both in the presence and absence of protein S and FV-short. Similarly, AndA-bound TFPIα was unable to inhibit FIXa and FXa generation by tissue factor (TF)-FVIIa in the absence of protein S and FV-short. However, in their presence, AndA-TFPIα inhibited FIXa generation, with a 50% inhibitory concentration of 0.14nM compared with that of 0.05nM for FXa-TFPIα. Similarly, the assays of FXa generation showed inhibition of TF-FVIIa-mediated FX activation at saturating concentrations of AndA in the presence of protein S and FV-short. Although AndA reduces TFPIα function by competing with FXa for TFPIα interactions, it does not fully block TFPIα. Protein S and FV-short enable AndA-bound TFPIα to locate at the membrane surface to inhibit TF-FVIIa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.